Skip to main content
Alteogen Inc. logo

Alteogen Inc. — Investor Relations & Filings

Ticker · 196170 ISIN · KR7196170005 KO Professional, scientific and technical activities
Open in API
Filings indexed 293 across all filing types
Latest filing 2024-11-18 AGM Information
Country KR South Korea
Listing KO 196170

About Alteogen Inc.

http://www.alteogen.com/

Alteogen Inc. is a biopharmaceutical company focused on the development and commercialization of next-generation biologics. The company's core activities are centered on its proprietary platform technologies. These include Hybrozyme™, a novel recombinant human hyaluronidase (ALT-B4) technology that enables the conversion of intravenous (IV) therapies to subcutaneous (SC) formulations, enhancing patient convenience. Additionally, Alteogen develops long-acting biobetters utilizing its NexP™ fusion technology, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. The company's pipeline is aimed at creating therapies with enhanced efficacy and delivery methods for serious diseases.

Recent filings

Filing Released Lang Actions
주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for the company Alteogen, detailing the date, time, location, and agenda items (specifically a proposal to amend the articles of incorporation). This type of document is a standard proxy solicitation or meeting notice sent to shareholders to inform them of an upcoming meeting and the matters to be voted upon. Given the provided categories, 'PSI' (Proxy Solicitation & Information Statement) is the most accurate classification for a notice of meeting and agenda.
2024-11-18 Korean
[기재정정]회사합병결정(종속회사의주요경영사항)
M&A Activity Classification · 100% confidence The document is a regulatory filing regarding a 'Company Merger Decision' (회사합병 결정) involving a subsidiary. It details the merger method, ratio, schedule, and board resolution dates. This falls under the category of M&A activity (mergers and acquisitions).
2024-11-14 Korean
[기재정정]타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a regulatory filing from a Korean company (Alteogen) regarding the acquisition of shares in another entity (Altos Biologics). It specifically details a 'Decision to Acquire Shares and Securities of Another Corporation' (타법인주식및출자증권취득결정) and includes a correction notice (정정신고) for the acquisition schedule. This type of corporate disclosure regarding investment activities, M&A-related share acquisitions, and capital structure changes falls under the 'Regulatory Filings' category as it is a specific disclosure requirement for listed companies in Korea.
2024-11-14 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Alteogen, covering the period from January 1, 2024, to September 30, 2024. It contains detailed corporate information, financial data, management discussions, and shareholding information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
투자판단관련주요경영사항 (인간 히알루로니다제 원천 기술(ALT-B4) 독점적 라이선스 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (DART system) titled 'Investment Judgment Related Major Management Matters'. It details a specific licensing agreement (ALT-B4 technology) between Alteogen and Daiichi Sankyo. This type of filing is a standard corporate disclosure for material events, specifically M&A or licensing/partnership activity, which falls under the 'TAR' (M&A Activity) category as it relates to a significant business transaction/partnership agreement.
2024-11-08 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement (863 characters) regarding the scheduling of an Investor Relations (IR) meeting. It provides the date, time, location, and purpose of the meeting, and mentions that the IR materials will be posted on the KRX website. Since it is an announcement of an event/presentation rather than the presentation itself, and it serves as a regulatory notification of corporate activity, it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing an IR event, RPA is the most accurate classification.
2024-11-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.